● Recruiting

A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)

Condition: Non Small Cell Lung Cancer · EGFR Activating Mutation · EGFR DEL19 · Sponsor: Intergroupe Francophone de Cancerologie Thoracique

PhaseNA

Planned participants300

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

IFCT-2202 ROSIE study aims to incorporate a broad-panel centralized NGS testing at baseline in all patients with completely resected NSCLC with common EGFR mutation after confirmation of an optimal preoperative extension assessment and with a centralized review of the quality of the surgical excision. Furthermore, the IFCT-2202 ROSIE study also aims to study the molecular events associated with relapse on, or after osimertinib exposure, that should result in the opportunity to accede to optimal treatment in case of metastatic relapse.

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (36)

Angers - CHU	Angers, France	Recruiting
Bayonne - CH	Bayonne, France	Recruiting
Boulogne - Ambroise Paré	Boulogne, France	Recruiting
Lyon - URCOT	Bron, France	Recruiting
Caen - CHU	Caen, France	Recruiting
Clermont-Ferrand - CHU	Clermont-Ferrand, France	Recruiting
Colmar - CH	Colmar, France	Recruiting
Créteil - CHI	Créteil, France	Recruiting
Dijon - CHU Bocage	Dijon, France	Recruiting
Grenoble - CHU	Grenoble, France	Recruiting
La Roche-Sur-Yon - CH	La Roche-sur-Yon, France	Recruiting
Le Mans - CHG	Le Mans, France	Recruiting

+ 24 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06053099